Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million
January 30, 2024 09:25 ET | Palisade Bio, Inc.
Carlsbad, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress
January 09, 2024 08:00 ET | Palisade Bio, Inc.
Carlsbad, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious...
Logo.png
Hepion Pharmaceuticals to Present at NASH-TAG 2024
January 03, 2024 17:15 ET | Hepion Pharmaceuticals, Inc.
EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Picture1.png
Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp Acquisition Corp.
December 27, 2023 08:01 ET | PowerUp Acquisition Corp.
Tarrytown, NY and New York, NY, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Visiox Pharmaceuticals, Inc. (“Visiox” or the “Company”), a commercial-stage biopharmaceutical company, and PowerUp Acquisition...
ARIDIS_LOGO.png
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
December 15, 2023 16:15 ET | Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective...
Logo 1.png
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company
December 14, 2023 07:50 ET | Aeterna Zentaris Inc
TORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative...
Logo.png
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
December 07, 2023 08:00 ET | Hepion Pharmaceuticals, Inc.
Restructuring program purpose is to preserve capital and optimize clinical development program Management plans to continue to evaluate its Phase 2b ASCEND-NASH clinical trial taking in account...
 Biocon Biologics personnel working at the insulin devices manufacturing facility in Bengaluru, India.
Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe
November 30, 2023 05:00 ET | Biocon Biologics
BENGALURU, India, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris’...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American
November 28, 2023 17:21 ET | Timber Pharmaceuticals
WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and...
Logo edited.jpg
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024
November 21, 2023 06:00 ET | Greenwich LifeSciences, Inc.
STAFFORD, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an...